NEW YORK, April 21, 2025 /PRNewswire/ -- DarioHealth Corp. (NASDAQ: DRIO) ("Dario" or the "Company"), a leading global digital health company, today announced that Zvi Ben-David, Chief Financial Officer, will retire from his role, effective May 15, 2025. The Company has appointed Chen Franco-Yehuda as its new Chief Financial Officer, Treasurer, and Secretary, and will assume the role upon Mr. Ben-David's retirement on May 15, 2025. To ensure a smooth transition, Mr. Ben-David will remain with the Company un ...

Strategic partnership expands Dario's employer footprint and has already started contributing to recurring revenues in Q1 of 2025 NEW YORK, April 17, 2025 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO) ("Dario" or the "Company"), a leader in the global digital health market, today announced a new strategic partnership with a leading benefit administrator to deliver its comprehensive cardiometabolic solution including a GLP-1 support program and full AI-driven digital health suite to employers, with initia ...

Second major healthcare employer signs with DarioHealth, accelerating growth in 2025 and reinforcing its leadership in AI-powered, clinically validated digital health solutions for chronic condition managementNEW YORK, April 8, 2025 /PRNewswire/ -- DarioHealth Corp. (NASDAQ: DRIO) ("Dario" or the "Company"), a leader in the global digital health market, today announced a new employer partnership with one of the nation's most respected research and medical institutions. The signed agreement is already live a ...

Investors might want to bet on DarioHealth Corp. (DRIO) , as it has been recently upgraded to a Zacks Rank #1 (Strong Buy). This upgrade is essentially a reflection of an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices.The sole determinant of the Zacks rating is a company's changing earnings picture. The Zacks Consensus Estimate -- the consensus of EPS estimates from the sell-side analysts covering the stock -- for the current and following years is tracked by th ...

Core Insights - DarioHealth has secured a new agreement with a Blue Cross Blue Shield (BCBS) health plan, enhancing its presence in the health plan market and driving recurring revenue growth [1][2][3] - The agreement integrates Dario's AI-driven cardiometabolic digital health solutions into the health plan's services, contributing to the company's annual recurring revenue (ARR) in Q1 2025 [2][4] - Dario now serves nine health plans, reinforcing its role in delivering digital cardiometabolic care solutions as the market is projected to exceed $1.2 trillion by 2033 [3][4] Company Overview - DarioHealth is a leader in the global digital health market, focusing on chronic condition management through a user-centric digital therapeutics platform [5][6] - The platform offers personalized interventions driven by data analytics and coaching for conditions such as diabetes, hypertension, and weight management [5][6] - Dario's approach aims to provide continuous and customized care, enhancing user satisfaction and promoting sustainable behavior change [6][7] Market Position - The collaboration with BCBS highlights the increasing demand for scalable, AI-driven digital health solutions among payers [4] - Dario's expansion into the multi-billion-dollar payer market is expected to strengthen its trajectory toward profitability and long-term growth [4][3] - The cardiometabolic disease market is identified as one of the fastest-growing sectors in healthcare, further solidifying Dario's strategic positioning [3][4]

DarioHealth Corp. (NASDAQ:DRIO) Q4 2024 Earnings Conference Call March 10, 2025 8:30 AM ET Company Participants Kat Parrella - Investor Relations Manager Erez Raphael - Chief Executive Officer Steven Nelson - Chief Commercial Officer Conference Call Participants Charles Rhyee - TD Cowen Ashok Kumar - ThinkEquity David Grossman - Stifel Operator Good morning, ladies and gentlemen, and welcome to the DarioHealth Fourth Quarter 2024 Results Conference Call. At this time, all lines are in listen-only mode. Foll ...

Core Insights - DarioHealth Corp. reported significant financial improvements for the fourth quarter and full-year 2024, with total revenue reaching $27.0 million, a 32.9% increase from $20.4 million in 2023, driven by strong growth in its B2B2C business [4][26][27] Financial Performance - Total revenue for 2024 was $27.0 million, up 32.9% from $20.4 million in 2023 [4][26] - Recurring revenues from the B2B2C segment grew to $20.0 million in 2024, a 300% increase from $5 million in 2023 [27] - Gross profit for 2024 was $13.3 million, a 122% increase from $6.0 million in 2023 [28] - Operating loss for 2024 was $57.7 million, slightly higher than the $56.2 million loss in 2023, primarily due to increased operating expenses [31] Business Model and Strategy - Dario has transitioned to a SaaS-like model with high-margin, recurring revenues based on multi-year contracts [2] - The acquisition of Twill Inc. has enhanced Dario's position in the digital health market, allowing it to support five chronic conditions under a unified brand [3] - The company secured 36 new clients in 2024, bringing the total client base to 83, with a forecast of 50% net client growth in 2025 [6][11][15] Market Trends and Demand - There is a growing demand for comprehensive chronic care solutions, particularly those that complement GLP-1 therapies, as employers and health plans seek long-term support beyond medication [7][10] - Dario's AI-driven platform is positioned to meet the increasing demand for efficiencies in digital health, leveraging data from 5 million patients to enhance engagement and outcomes [10] Operational Efficiency - The company implemented cost-management strategies that led to a 35% reduction in operating loss from Q1 2024 to Q4 2024 [5] - Dario anticipates an additional 20% reduction in operating expenses by Q4 2025 through further consolidation and AI tool implementation [5][40] Client Engagement and Retention - Dario maintains a client renewal rate above 90%, indicating strong value and impact of its solutions [12] - The company’s contracts are primarily structured as three-year agreements, providing long-term stability [12] Future Outlook - Dario aims to accelerate growth by expanding its reach into mid-sized employers and maximizing existing collaborations with health plans [15] - The company expects to achieve an operational cash flow breakeven run rate by the end of 2025 [5][40]

Business Growth and Client Acquisition - DarioHealth has signed over 100 total contracts as of now, indicating rapid scaling of its B2B2C model [559]. - In the fiscal year 2024, the B2B2C channel added 36 new employers and health plan clients, bringing the total client base to 83 [574]. - The company has expanded its solutions beyond diabetes to include hypertension, pre-diabetes, musculoskeletal health, and behavioral health [559]. - The company has entered into contracts with a preferred partner and a health plan provider for data licensing and implementation services [575]. Financial Performance - Revenues for the year ended December 31, 2024, amounted to $27,040, an increase of 33.2% compared to $20,352 for the year ended December 31, 2023, driven by growth in the commercial channel and the consolidation of Twill's revenues [584]. - Gross profit for the year ended December 31, 2024, was $13,267, representing 49.1% of revenues, compared to $5,984 or 29.4% of revenues for the year ended December 31, 2023 [588]. - Net loss for the year ended December 31, 2024, was $42,747, a decrease of 28.2% from the net loss of $59,427 for the year ended December 31, 2023 [600]. - As of December 31, 2024, the company had incurred an accumulated deficit of $390,343 since inception [611]. - The company expects to continue incurring losses until it achieves profitability through successful product development and commercialization [611]. Cash Flow and Capital Management - Cash and cash equivalents as of December 31, 2024, were approximately $27,764, down from $36,797 at December 31, 2023 [612]. - Net cash used in operating activities increased to $38.562 million for the year ended December 31, 2024, compared to $30.379 million in 2023, primarily due to increased operating expenses and working capital [636]. - Net cash used for investing activities rose to $8.934 million in 2024, significantly higher than $547, attributed to the acquisition of Twill [637]. - Net cash provided by financing activities was $38.531 million for the year ended December 31, 2024, compared to $18.253 million in 2023, driven by private placements [638]. - The company expects to meet its contractual obligations totaling $4.884 million, with $3.948 million due within one year [640]. Mergers and Acquisitions - The company acquired Upright for a total consideration of 1,687,612 shares of common stock and options to purchase up to 100,193 shares [560]. - DarioHealth paid $10.0 million in cash as part of the merger with Twill, along with additional stock options and warrants [561]. - Research and development expenses increased by $3,931 to $24,179 for the year ended December 31, 2024, primarily due to higher payroll and consulting expenses related to the consolidation of Twill [590]. - Sales and marketing expenses rose by $2,565 to $26,350 for the year ended December 31, 2024, mainly due to increased payroll and consulting expenses from the Twill acquisition [592]. - General and administrative expenses increased by $2,342 to $20,482 for the year ended December 31, 2024, largely due to higher payroll and acquisition costs associated with Twill [594]. Regulatory and Accounting Changes - The FASB issued ASU 2023-07, effective January 1, 2024, enhancing segment reporting disclosures, particularly on significant segment expenses [644]. - ASU 2023-09, effective January 1, 2025, requires disaggregated information on effective tax rate reconciliation and income taxes paid, currently under evaluation [645]. - ASU 2024-03 mandates additional disaggregated disclosures for certain expense categories, effective after December 15, 2026, with early adoption permitted [646]. - The company adopted the fiscal year standard for segment disclosures on a retrospective basis starting January 1, 2024 [644]. - The impact of ASU 2023-09 on financial statement disclosures is currently being evaluated by the company [645]. - The company is assessing the effects of adopting ASU 2024-03 on its disclosures [646]. - No quantitative or qualitative market risk disclosures are applicable at this time [647].

Core Insights - DarioHealth Corp. has announced a strategic collaboration with Rula Health to enhance access to mental health support for employers and their workforce nationwide [1][2][3] - The partnership allows Dario to leverage Rula's network of over 15,000 providers, covering over 120 million commercial lives through major insurance networks [1][7] - This collaboration aims to accelerate the adoption of Dario's behavioral health solutions in the employer channel and boost sales growth in the B2B2C segment [2][3] Company Overview - DarioHealth is a leader in the digital health market, focusing on chronic condition management through a user-centric digital therapeutics platform [5] - The company's solutions include personalized interventions driven by data analytics and coaching for various health issues, including behavioral health [5][6] - DarioHealth provides its solutions globally to health plans, self-insured employers, and consumers [6] Rula Health Overview - Rula Health offers a network of over 15,000 licensed providers, providing next-day therapy and 24/7 crisis support [7] - The platform allows patients to quickly match with providers, confirm insurance costs, and track their progress [7][8] - Rula Health accepts most major insurance networks, covering over 120 million lives [8]

Core Insights - DarioHealth Corp. has signed a contract with a major healthcare system to provide AI-powered chronic care management solutions, expected to contribute to 15 new client signings in 2025, marking a significant step towards achieving its net new client goal for that year [1][2][3] Company Developments - The new contract is set to go live in the first quarter of 2025, reinforcing the recognition of digital health solutions among healthcare professionals [2][3] - Dario's solutions are designed to enhance care delivery for chronic conditions such as diabetes, hypertension, musculoskeletal pain, and mental health challenges, reflecting confidence from self-insured employers in the company's value proposition [3][4] Industry Trends - The digital health landscape is evolving, with collaborations between digital health companies and healthcare systems becoming critical for expanding access to technology-enabled care [6] - Recent industry shifts, including improved coverage and stronger clinical evidence, are accelerating the adoption of digital wellness and self-care therapies, which have historically faced skepticism [5][6] Clinical Effectiveness - Dario's platform has demonstrated effectiveness in reducing A1C levels for diabetes patients by 2.3 points and decreasing anxiety and depression by 28-30% over eight weeks through its behavioral health platform, Dario Mind [4] - The company aims to bridge the gap between traditional care models and scalable digital interventions by combining AI-driven personalization with a seamless user experience [4][8] User-Centric Approach - Dario's user-centric platform offers continuous and customized care, empowering individuals to adapt their lifestyles for sustainable behavior change, which drives user satisfaction and retention [8] - The company provides its solutions globally to health plans, self-insured employers, and consumers, emphasizing a holistic approach to chronic condition management [9]